

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/008,354	11/07/2001	Julio C. Spinelli	279.373US1	4381
21186	7590 09/27/2006		EXAMINER	
SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. BOX 2938 MINNEAPOLIS, MN 55402			EVANISKO, GEORGE ROBERT	
			ART UNIT	PAPER NUMBER
		•	3762	
			DATE MAILED: 09/27/2006	5

Please find below and/or attached an Office communication concerning this application or proceeding.

<u> </u>	
L.	
address	
(30) DAYS,	
s communication.	
the merits is	
CFR 1.121(d). PTO-152.	

		Application No.	Applicant(s)				
		10/008,354	SPINELLI ET AL.				
	Office Action Summary	Examiner	Art Unit				
		George R. Evanisko	3762				
Pariod fo	The MAILING DATE of this communication app						
Period for Reply							
WHIC - Exter after - If NO - Failu Any	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DYNAMING OF THE MAILING OF THE M	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE.	N nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)⊠	Responsive to communication(s) filed on <u>12 September 2006</u> .						
2a)□	This action is FINAL . 2b)⊠ This	action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims						
4)⊠	4) Claim(s) 1-46 is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
5)□	5) Claim(s) is/are allowed.						
	6)⊠ Claim(s) <u>1-4,6,7,10-18,20,21,24-26,30-41,43 and 46</u> is/are rejected.						
	7) Claim(s) <u>5,8,9,19,22,23,27-29,42,44 and 45</u> is/are objected to.						
8)[_]	Claim(s) are subject to restriction and/o	r election requirement.					
Applicati	on Papers						
9)[The specification is objected to by the Examine	· ·r.					
10)[The drawing(s) filed on is/are: a) ☐ acc	epted or b)□ objected to by the I	Examiner.				
	Applicant may not request that any objection to the	drawing(s) be held in abeyance. See	e 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority (ınder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
	1. Certified copies of the priority documents have been received.						
	2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
			•				
Attachmen							
	1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 4) Interview Summary (PTO-413) Paper No(s)/Mail Date						
3) Information Disclosure Statement(s) (PTO/SB/08) 5) Notice of Informal Patent Application							
Paper No(s)/Mail Date 6) Other:							

DETAILED ACTION

Response to Amendment

The applicants arguments are persuasive and the finality of the rejection of the last Office action is, therefore, withdrawn.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-4, 6, 7, 10, 12-18, 20, 21, 24-26, 30, 32-35, 37-41, 43, and 46 are rejected under 35 U.S.C. 102(e) as being anticipated by Bardy (7070562). Bardy teaches the use of an IMD storing data characteristic of a patient (column 5), transmitting the information to a programmer, 14, and then over a wide area network (the internet, column 6), to a remote server. The remote server analyzes the data and provides feedback (the claimed "prescribing") to the programmer to reprogram instructions in the IMD (e.g. column 9, claim 1, etc). The remote server contains several "expert prescription systems", such as peer-to-peer and sibling-to-sibling (column 10), since these different comparisons are set up, defined, and implemented by experts/physician/technicians to determine when to reprogram the device. In addition, these same prescription systems are considered the "custom prescription system" since they are customized to the particular patient and/or IMD. Regarding claims 12, 13, and 14, the IMD is

considered to be a patient monitoring system and a patient records computer system since the IMD both monitors and records patient information and interfaces with the programmer.

Claims 1-3, 6, 10-17, 20, 24-26, 30-41, 43, and 46 are rejected under 35 U.S.C. 102(e) as being anticipated by Haller et al (2002/0013613). Haller teaches the use of an IMD storing data characteristic of a patient (e.g. paragraph 88), transmitting the information to a programmer, 100/110, and then over a wide area network to a remote expert data center (paragraph 81). It is noted that device 100/110 is a programmer since it receives information from the IMD and programs the IMD with new parameters (e.g. paragraphs 89, 105, etc). The remote server analyzes the data and provides feedback (the claimed "prescribing", paragraph 169) to the programmer to reprogram instructions in the IMD. The device/programmer 100 has a user interface 108 that accepts characteristics of the patient to reprogram the device (e.g. paragraphs 96, 163). Regarding claims 12, 13, and 14, the IMD is considered to be a patient monitoring system and a patient records computer system since it both monitors and records patient information and interfaces with the programmer. The remote server contains an expert system since it is called an expert system or contains a custom prescription system since the device is customized to the particular patient and/or IMD.

Claims 1-3, 6, 10, 12-17, 20, 24-26, 30, 32-35, 37-41, 43, and 46 are rejected under 35 U.S.C. 102(e) as being anticipated by Snell (6249705). Snell teaches the use of an IMD transmitting patient data to the programmer (column 8, lines 26-35) and the server analyzing the data and prescribing new parameters for the IMD (column 9, lines 30-45). Regarding claims 12, 13, and 14, the IMD is considered to be a patient monitoring system and a patient records computer system since it both monitors and records patient information and interfaces with the

programmer. The remote server contains an expert system or custom prescription system since it is provided by experts/physicians/technicians to accurately program the device and since the device is customized to the particular patient and/or IMD.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 4, 7, 18, and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Haller et al or Snell. Haller or Snell discloses the claimed invention except for the multiple expert and/or custom prescription systems. It would have been obvious to one having ordinary skill in the art at the time the invention was made to modify the prescription method and system as taught by Haller or Snell, with the use of multiple expert and/or custom prescription systems since it was known in the art that prescription systems use multiple expert and/or custom

prescription systems to allow different rules to be applied to different patient parameters in order to program different functions, such as pacing rate, defibrillation therapy, sensor rate, etc, in the IMD to meet the hemodynamic and therapeutic needs of the patient.

Allowable Subject Matter

Claims 5, 8, 9, 19, 22, 23, 27-29, 42, 44, and 45 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims.

Response to Arguments

Applicant's arguments with respect to the claims have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. Duffin shows a similar cellular phone programmer as Haller.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to George R. Evanisko whose telephone number is 571 272 4945. The examiner can normally be reached on M-F 6:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Angela Sykes can be reached on 571 272 4955. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 10/008,354

Art Unit: 3762

Information regarding the status of an application may be obtained from the Patent
Application Information Retrieval (PAIR) system. Status information for published applications
may be obtained from either Private PAIR or Public PAIR. Status information for unpublished

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR

system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would

like assistance from a USPTO Customer Service Representative or access to the automated

information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

George R Evanisko Primary Examiner Art Unit 3762 Page 6

GRE September 20, 2006